ImmunoGen Inc (IMGN)

[skitahoe]

It seems like investors don't like what IMGN said, even though it's essentially what they've been saying all along. A new trial will be started this year that could have IMGN853 approve by about 2022.

I'll admit, their presentation put me to sleep, so I cannot speak to every word, but I believe they've learned much from the failed trial, and the patients in the new trial will be better qualified to receive the maximum benefits. In the failed trial there are certainly a number of patients who're still alive who wouldn't have expected to be with the SOC, but that's not the acceptance criteria. It's sad, investigators can clearly see a certain group that benefits, yet the regulators can't see it being definitive enough to approve the drug with a limited label.

Gary